| Pharmaceutical active ingredients: |
| Ropinirole Hydrochloride |
| Available forms, composition and doses of Requip: |
| Tablets, Film-Coated; Oral; Ropinirole Hydrochloride 0.25 mgTablets, Film-Coated; Oral; Ropinirole Hydrochloride 0.5 mgTablets, Film-Coated; Oral; Ropinirole Hydrochloride 1 mgTablets, Film-Coated; Oral; Ropinirole Hydrochloride 2 mgTablets, Film-Coated; Oral; Ropinirole Hydrochloride 5 mgTablets; Oral; Ropinirole Hydrochloride 0.25 mgTablets; Oral; Ropinirole Hydrochloride 0.5 mgTablets; Oral; Ropinirole Hydrochloride 1 mgTablets; Oral; Ropinirole Hydrochloride 2 mgTablets; Oral; Ropinirole Hydrochloride 3 mgTablets; Oral; Ropinirole Hydrochloride 4 mgTablets; Oral; Ropinirole Hydrochloride 5 mg |
| Requip medical category: |
| Human:Antiparkinsonian drugsNonergot-derivative dopamine receptor agonists |
| Indications and usages, anatomical therapeutic chemical and diseases classification codes: |
| N04BC04 - Ropinirole |
| Pharmaceutical companies: manufacturers, researchers, developers, local distributors and suppliers: |
| GlaxoSmithKlineZuellig Pharma |
| Related documents and information about Requip: |
| Requip prescribing information (PDF)Requip XL prescribing information (PDF) |